Home / Equities / ASX200 slide continues

ASX200 slide continues

Equities

ASX200 slide continues, tech darlings under pressure, Altium (ASX:ALU) revenue falls, weaker open ahead

The ASX200 (ASX:XJO) couldn’t hold sustain early gains, falling another 0.3% on Tuesday with the financial sector the only real positive.

National Australia Bank (ASX:NAB) lead the sector higher adding 1.1% as signs of higher bond rates are likely to support higher net interest margins.

  • Selling pressure continued to build on the technology sector after Altium Ltd (ASX:ALU) reported a 3% fall in first half revenue as challenging conditions in the US and China put an ‘unprecedented drag’ on sales of the company’s chip design software.

    This came as a surprise given the huge demand for processing power and incredible shift to digital platforms throughout 2020; shares finished 2.2% as a result.

    Four wheel driver accessory distributor ARB Corporation (ASX:ARB) offered a positive surprise, with the company capitalising on the ‘holiday at home’ trend reporting a 21.6% increase in sales compared to 2019 levels, sending revenue to $284 million for the first half. Management now expect profit of between $70 and $72 million, shares finished 5.8% higher.

    Whilst a positive result the company is now doubled in value in less than 12 months and now trades on a valuation similar to a fast-growing tech company; this may be a stretch given the potential of a return to normal travel in 2021.

    Origin Energy (ASX:ORG) goes renewable, Avita Medical (ASX:AVH) jumps 15.3%

    Origin Energy (ASX:ORG) announced plans to develop a 700MW battery at their Eraring coal-fired power station, Australia’s largest, in an effort to reduce pressure on the ailing electricity grid and likely cut the costs associated with their ageing asset.

    Avita Medical (ASX:AVH), a favourite of fund managers and brokers alike for its special burns’ treatments jumped 15.3% after reporting revenue of USD$5 million in the second quarter of 2021 from its primary RECELL treatment and USD$5.1 million in total global revenue, an increase of 57% on 2019 levels.

    The company, whose shares are down over 60% over the last 12 months, reported a 9% decrease in their cash holdings as the struggle to gain traction in major hospitals.

    Similarly, Polynovo (ASX:PNV) fell 13.0% despite reporting a 31% increase in sales in the first half despite slower than expected sales in October and November.

    The company is showing strong progress with a number of large hospitals signing purchase orders and the group reporting 89% growth in trading accounts throughout 2020.

    Both these results evidence the incredibly difficult task for biotech companies to bring innovative products to market on commercial terms.

    US stocks pause ahead of earnings season, Trump impeachment commenced, social sell off continues

    The value shift continued in US markets overnight, with the energy and financial sectors gaining most, sending the Dow Jones up 0.2%, with the Nasdaq also adding 0.3%.

    The primary driver was more positives on the supply side of oil markets with US shale producers confirming their intention not to increase production in an oversupplied market, sending the oil price to a ten month high above USD$50 per barrel.

    Major oil names including BP (NYSE:BP) and Chevron Inc. (NYSE:CVX) who added 2.6% and 1.9%.

    E-commerce business Etsy (NASDAQ:ETSY) rallied another 12.1%, as the reseller of vintage and handmade goods is expected to report a strong final quarter.

    Consumers and investors seem to be responding to censorship decision made by the likes of Amazon (NASDAQ:AMZN) and Twitter (NASDAQ:TWTR), both falling another 2.0%.

    The US Congress plans to vote on a second impeachment of President Trump, which is mostly symbolic given the short-time before his term ends next week.




    Print Article

    Related
    ASIC levy review targets adviser ‘time-lag’ issue

    The review will consider “the consequences of time lags between regulatory action and cost allocation”, the terms of reference states.

    Tahn Sharpe | 11th Aug 2022 | More
    AMP Advice to ‘break even’ by 2024 as losses soften

    The institutional provider’s AUM and profit lines stayed red in 1H22, but positive signs emerged.

    Tahn Sharpe | 11th Aug 2022 | More
    INBrief with Gabriel Carey from Cadre Capital

    Gabriel Carey from Cadre Capital speaks with Jamie Nemtsas at The Inside Network’s Income & Defensive Assets Symposium.

    The Inside Adviser | 10th Aug 2022 | More
    Popular
    1
    Advisers urged to tread carefully with ‘wholesale investor’ status
    Staff Writer | 28th Jul 2022 | More
    2
    Top hedge fund award goes to L1 Capital
    Greg Bright | 13th Dec 2021 | More
    3
    MAX Award winners and the new world outside
    Greg Bright | 13th Jun 2022 | More
    4
    Quality of advice review focused on advisers, not consumers
    Drew Meredith | 11th Jul 2022 | More
    5
    INDepth with Andrew Lockhart from Metrics Credit Partners
    The Inside Adviser | 30th Jun 2022 | More